267 related articles for article (PubMed ID: 24840285)
1. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort.
Piga M; Chessa E; Ibba V; Mura V; Floris A; Cauli A; Mathieu A
Autoimmun Rev; 2014 Aug; 13(8):873-9. PubMed ID: 24840285
[TBL] [Abstract][Full Text] [Related]
2. [Biologics-Induced Kidney Injury -with Special Attention to Anti-Rheumatic Drugs -].
Kimura H
Rinsho Byori; 2016 Jun; 64(6):718-722. PubMed ID: 30695331
[TBL] [Abstract][Full Text] [Related]
3. Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review.
Chessa E; Piga M; Floris A; Congia M; Cangemi I; Mathieu A; Cauli A
BioDrugs; 2021 Mar; 35(2):175-186. PubMed ID: 33595833
[TBL] [Abstract][Full Text] [Related]
4. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
6. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
7. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
8. Biological Therapy-Induced Systemic Vasculitis.
Gutiérrez-González LA
Curr Rheumatol Rep; 2016 Jul; 18(7):39. PubMed ID: 27165496
[TBL] [Abstract][Full Text] [Related]
9. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
Singh JA
Curr Rheumatol Rep; 2016 Oct; 18(10):61. PubMed ID: 27613285
[TBL] [Abstract][Full Text] [Related]
10. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
11. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
12. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
14. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.
Ozguler Y; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Borekci S; Atahan E; Ongen G; Hamuryudan V
Rheumatol Int; 2016 Dec; 36(12):1719-1725. PubMed ID: 27699578
[TBL] [Abstract][Full Text] [Related]
15. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
16. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
Al-Mayouf SM; Alenazi A; AlJasser H
Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
[TBL] [Abstract][Full Text] [Related]
17. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
18. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.
Confavreux CB; Chapurlat RD
Osteoporos Int; 2011 Apr; 22(4):1023-36. PubMed ID: 20959960
[TBL] [Abstract][Full Text] [Related]
19. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
[TBL] [Abstract][Full Text] [Related]
20. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
Harigai M; Nanki T; Koike R; Tanaka M; Watanabe-Imai K; Komano Y; Sakai R; Yamazaki H; Koike T; Miyasaka N
Mod Rheumatol; 2016 Sep; 26(5):642-50. PubMed ID: 26873430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
